Period-dependent survival benefit of percutaneous microwave ablation for hepatocellular carcinoma: 12-year real-world multicentric experience
Jie Yu, Zhi-Gang Cheng, Zhi-yu Han and 10 more
Liver Cancer · 2022
doi:10.1159/000522134 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction: Although being a promising technique for hepatocellular carcinoma (HCC) treatment, the 10-year efficacies of microwave ablation (MWA) are unknown. Objective: To assess whether the advances of MWA for HCC translated into a real-world survival benefit. Methods: This retrospective study included 2,354 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 to B from 5 hospitals, with at least 2 years of follow-up for all the patients. Recurrence and survival were analyzed using the Kaplan-Meier method with time-period stratification. Results: A total of 5,326 HCCs (mean diameter, 2.9 cm ± 1.2) underwent 4051 sessions of MWA with a median follow-up of 61.3 (ranging 0.6–169.5) months during three time-periods of 2007–2010, 2011–2014, and 2015–2018.Technical success was achieved in 5,194 (97.5%) tumors with significant improvement over time, especially for > 3.0 cm HCC (p 3.0 cm HCC and perivascular location were the risk factors for LTP. The median intra-hepatic metastasis time was 27.6 (95% CI 25.2–28.8) months, with 5- and 10-year occurence rate of 68.8% and 79.4%, respectively. The 5- and 10-year overall survival were 63.9% and 41.1%, respectively, and BCLC stage 0, A, B patients all with an observable survival improvement over time(p<0.001). The median disease-free survival time increased from 19.4 (95% CI 16.5–22.6) months in 2007–2010 to 28.1 (95% CI 25.9–32.3) months in 2015–2018. The improved survival for early recurrent (≤ 2 years)patients was period- dependent as verified by Cox regression analyses. The major complications rate per procedure was 2.2% (88/4051). Conclusions: These real-world data show MWA provided anupward trend in survivalfor HCC patients with BCLC stage 0–B over a 12-year follow-up time. A clear survival benefit in early recurrent patients was also observed encouragingly.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.